Pioneers in cell therapy and regenerative medicine
We develop cutting-edge therapies and implants for unresolved chronic diseases and address the growing challenges of the biomedical industry through visionary biotools.
Our Mission
To drive translational research, development, and commercialization of biotechnological platforms that provide innovative solutions to currently unmet chronic diseases and address the growing challenges of the biomedical industry.
Our Vision
We aspire to become a global catalyst for regenerative medicine companies and products that help facilitate access to advanced medical treatments with significant impact on patients’ health and well-being.
Our values
Integrity, respect for life, and the dignity of individuals
Excellence in all our activities
Quality and safety of our products
Innovation in our technological developments
Leadership in our fields of expertise
Our objective
Cells for Cells is strongly committed to achieving clinical and intellectual property validation in the shortest possible time and with maximum efficiency, a commitment that enabled us to become the first company to treat a patient with exosomes for an osteoarticular disease.
We seek to reduce the risk of a range of assets related to regenerative medicine, which may then follow a licensing or spin-off. Our objective is to provide hope to patients who urgently need effective medical solutions, while reducing costs and geographic barriers to access advanced therapeutic products.
First, Quality
At Cells for Cells, we are committed to quality.
Since 2010, we have defined the forefront of Regenerative Medicine in Latin America. We not only lead the production of cell therapies, but also set the standard of excellence. Our commitment is simple: unwavering quality and continuous improvement (Kaizen).
We operate under Good Manufacturing Practices (GMP) and ISO 9001:2015 certification because we believe that only maximum rigor and incremental refinement can ensure that every advance translates into a safe and tangible improvement in our patients’ lives. We lead Regenerative Medicine in LATAM, setting standards of excellence and operating under GMP and ISO 9001:2015.
Our History
More than 15 years of experience in developing cell therapies
2025
- Awarding of public funding for the construction of a CMO for advanced therapies in Chile.
- EvastBio – a C4C spinoff – nominated as a finalist for Technology Award of the Year
- Agreement signed with Mayo Clinic and publication of Cellistem EV technology for knee injection with exosomes.
2024
- Start of clinical series for androgenetic alopecia.
2023
- Creation of EvastBio in the United States.
2022
- C4C announces at the annual ISCT congress in San Francisco the clinical results of the first patient treated with an exosome-produced therapy for osteoarthritis.
2021
- C4C receives funding of 12.828 million pesos to create the region’s first Center of Excellence in Cell Therapy, named the Center of Interventional Medicine for Precision and Advanced Cellular Therapy (IMPACT).
2020
- Cells for Cells wins the 2020 National Innovation Award (Avonni Award) with its Venitis™ bioengineered vascular graft technology.
2019
- International expansion with the first clinical trial outside Chile (Colombia, FOSCAL).
- Publication in Nature on vascular technology.
2018
- The first clinical study in Latin America using cell therapy for the treatment of osteoarthritis is published
- Clínica Universidad de los Andes and Cells for Cells open the first Cell Therapy Center in Chile.
2017
- C4C’s GMP laboratory becomes the first Latin American cell therapy lab to comply with ISO 9001:2015 certification.
- First clinical trial with positive results for heart failure (Circulation Research, AHA), reported in international media in more than 14 languages.
2014
- Foundation of Regenero, Chile’s first regenerative medicine consortium, in partnership with Clínica Dávila and Universidad de los Andes.
- Inauguration of the GMP Cell Therapy Production Laboratory, located at Clínica Universidad de los Andes.
2012
- Inauguration of the Cells for Cells laboratories at the Center for Research and Innovation in Biomedicine at Universidad de los Andes.
- Start of the Phase I/II clinical trial of allogeneic cell therapy for heart failure.
2010
- Publication of a pioneering study on the use of expanded stem cells for the treatment of lupus
- Founding of Cells for Cells S.A.
